



## Development of tacrine clusters as positively cooperative systems for the inhibition of acetylcholinesterase

Tereza Cristina Santos Evangelista, Óscar López, Sabrina Baptista Ferreira, José G. Fernández-Bolaños, Magne O. Sydnes & Emil Lindbäck

To cite this article: Tereza Cristina Santos Evangelista, Óscar López, Sabrina Baptista Ferreira, José G. Fernández-Bolaños, Magne O. Sydnes & Emil Lindbäck (2021) Development of tacrine clusters as positively cooperative systems for the inhibition of acetylcholinesterase, Journal of Enzyme Inhibition and Medicinal Chemistry, 36:1, 1658-1663, DOI: [10.1080/14756366.2021.1954917](https://doi.org/10.1080/14756366.2021.1954917)

To link to this article: <https://doi.org/10.1080/14756366.2021.1954917>



© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



[View supplementary material](#)



Published online: 22 Jul 2021.



[Submit your article to this journal](#)



Article views: 715



[View related articles](#)



[View Crossmark data](#)

BRIEF REPORT



## Development of tacrine clusters as positively cooperative systems for the inhibition of acetylcholinesterase

Tereza Cristina Santos Evangelista<sup>a,b</sup>, Óscar López<sup>c</sup>, Sabrina Baptista Ferreira<sup>b</sup>, José G. Fernández-Bolaños<sup>c</sup>, Magne O. Sydnes<sup>a</sup> and Emil Lindbäck<sup>a</sup>

<sup>a</sup>Department of Chemistry, Bioscience and Environmental Engineering, Faculty of Science and Technology, University of Stavanger, Stavanger, Norway; <sup>b</sup>Department of Organic Chemistry, Chemistry Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; <sup>c</sup>Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, Seville, Spain

### ABSTRACT

The synthesis of four tetra-tacrine clusters where the tacrine binding units are attached to a central scaffold *via* linkers of variable lengths is described. The multivalent inhibition potencies for the tacrine clusters were investigated for the inhibition of acetylcholinesterase. Two of the tacrine clusters displayed a small but significant multivalent inhibition potency in which the binding affinity of each of the tacrine binding units increased up to 3.2 times when they are connected to the central scaffold.

### ARTICLE HISTORY

Received 19 May 2021  
Revised 6 July 2021  
Accepted 8 July 2021

### KEYWORDS

Acetylcholinesterase; CuAAC; multivalent interactions; multivalent inhibition potency; tacrine

### Introduction

Multivalent interactions (or multivalency) constitute a widespread recognition phenomenon in living organisms to establish interactions between carbohydrates and proteins, which are essential for the adhesion of viruses and bacteria to the surface of a cell in addition to cell adhesion<sup>1</sup>. The power of multivalent interactions is that when several binding modules are connected to a central scaffold and bind cooperatively to a target, the binding affinity of the multivalent ligand on a valency-corrected basis ( $rp/n$ ) can be dramatically increased (i.e. the binding affinity of the multivalent ligands is stronger than the sum of its mono-valent ligands alone), which is known as the cluster effect or multivalent effect<sup>2</sup>. A well-researched field in bioorganic chemistry is the synthesis of multivalent glycoconjugates for investigation of the multivalent effect for carbohydrate-protein (lectin) interactions<sup>2b,3</sup>. On a valency-corrected basis, such multivalent assemblies of carbohydrates have achieved an affinity enhancement of an astonishing six orders of magnitude for the binding to lectins<sup>4</sup>. A much less explored field is multivalent enzyme inhibition, which has been associated with the fact that most enzymes possess a single deep active site that is expected to be less accessible for multimeric ligands than several binding pockets on the surface of lectins<sup>5</sup>. In fact, such pockets on the surface of lectins give rise to efficient chelating binding with multivalent glycoconjugates<sup>6</sup>, and therefore multivalent effect for enzyme inhibition has been disregarded<sup>5b</sup>. To the best of our knowledge, if we neglect bivalent enzyme inhibitors, multivalent enzyme inhibition potency has only been achieved for a few groups of enzymes including, glycosidases<sup>2a,3a,7</sup>, glycosyltransferases<sup>8</sup>, carbonic anhydrases<sup>9</sup>, and very recently for

cholinesterases<sup>10</sup>. In this context, it is worth mentioning that a 36 valent inhibitor has been demonstrated to give rise to an astonishing affinity enhancement of ca 4700-fold on a valency-corrected basis for the inhibition of  $\alpha$ -mannosidase<sup>2a,11</sup>, which emphasise the power of multivalent enzyme inhibition. However, there is no general linear correlation between valency and enzyme inhibition potency on a valency-corrected basis as observations have been made in which the inhibition on valency-corrected basis decrease by valency<sup>9a,12</sup>. Another parameter to consider in the design of efficient multivalent inhibitors is the choice of the scaffold where various types of scaffolds implement different spatial orientations of the inhitopes, which can affect the inhibition<sup>8,13</sup>. The length of the linkers connecting the central scaffold with its inhitopes has also been identified as an important parameter for efficient multivalent enzyme inhibition<sup>14</sup>.


Alzheimer's disease (AD) is a multifactorial progressive neurological disorder that represents the most common form of dementia<sup>15</sup>. Currently, there is no cure available for this devastating disease due to a lack of exact knowledge of its causes<sup>16</sup>. The cholinergic hypothesis suggests that the level of the neurotransmitter acetylcholine (ACh) is insufficient in the Alzheimer brain, which causes cognitive loss<sup>17</sup>. Therefore, inhibition of cholinesterases [acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE)] and thereby increasing the concentration of ACh in the brain is an attractive target for the treatment of AD<sup>18</sup>. One example of a cholinesterase inhibitor drug for palliative treatment of AD is tacrine (**1**) (Figure 1), which unfortunately was discontinued in 2013 as it results in liver damage<sup>19</sup>. When the structure of AChE was solved by X-ray crystallography<sup>20</sup>, an active gorge, lined with aromatic residues, penetrating ca 20 Å into the enzyme was recognised

**CONTACT** Emil Lindbäck  [emil.lindback@uis.no](mailto:emil.lindback@uis.no)  Department of Chemistry, Bioscience and Environmental Engineering, Faculty of Science and Technology, University of Stavanger, NO-4036 Stavanger, Norway

 Supplemental data for this article is available online at [here](https://doi.org/10.1080/14756366.2021.1954917).

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Figure 1.** Illustration of known AChE inhibitors **1** and **2** and the tetravalent architectures **3a–6a**, which are the target molecules in this paper.

hosting: (1) the active site including the catalytic triad and catalytic anionic binding subsite (CAS) nearby the bottom of the active gorge and (2) the peripheral anionic binding site (PAS) located at the interface of the active gorge.

When the structure of tacrine complexed with AChE was solved by X-ray crystallography, it was concluded that it binds to CAS in the solid state<sup>21</sup>. To establish interactions with both CAS and PAS, a bivalent strategy was pursued in which two tacrine rings were connected *via* a heptamethylene linker to obtain bis(7)-tacrine (**2**) (Figure 1) that is a ca 1000-fold stronger AChE inhibitor than tacrine, which was associated with simultaneous interactions with CAS and PAS<sup>22</sup>. The finding of the enhanced AChE inhibition by bis(7)-tacrine (**2**) triggered an avalanche of reported bivalent AChE inhibitors<sup>18,23</sup>.

The tetrameric structure of AChE that contains four catalytic subunits<sup>24</sup> led us to propose tetra-tacrines **3a–6a** (Figure 1) as multivalent AChE inhibitors. We argued that when the tacrine

rings are attached to the central sugar scaffold *via* linkers of optimal length they would employ the chelation effect<sup>5b</sup> to bind simultaneously to the active gorges of the AChE tetramer to form a stable AChE: tetra-tacrine complex. An alternative mechanism to achieve multivalent inhibition by tetra-tacrines **3a–6a** is due to a statistical binding effect<sup>5b</sup> caused by the increased effective concentration of the tacrine rings nearby the active gorges of AChE. Thus, in this paper we present: (1) the synthesis of the tetra-tacrines **3a–6a** (Figure 1), (2) the synthesis of the mono-tacrines **3b–6b**, and (3) the multivalent inhibition potencies of tetra-tacrines **3a–6a** against AChE by comparing them with reference compounds **3b–6b**.

## Materials and methods

### General procedures

DMF has dried over 4 Å molecular sieves (oven-dried). All reactions were carried out under an argon atmosphere unless otherwise specified. Microwave reactions were performed in a CEM Discover-SP, max power 300 W. TLC analyses were performed on Merck silica gel 60 F254 plates or Sigma-Aldrich aluminium oxide 60 F254 (neutral) plates using a UV light for detection. Silica gel NORMASIL 60<sup>®</sup> 40–63 μm or Aluminium oxide Sigma-Aldrich 58 Å pore size was used for flash column chromatography. NMR spectra were recorded on a Bruker Avance NMR spectrometer; <sup>1</sup>H NMR spectra were recorded at 400.13 or 850.13 MHz, <sup>13</sup>C NMR spectra were recorded at 100.61 or 213.76 MHz, in CDCl<sub>3</sub>, MeOD, or DMSO. Chemical shifts are reported in ppm relative to an internal standard of residual chloroform ( $\delta=7.26$  for <sup>1</sup>H NMR;  $\delta=77.16$  for <sup>13</sup>C NMR), residual methanol ( $\delta=3.31$  for <sup>1</sup>H NMR;  $\delta=49.00$  for <sup>13</sup>C NMR) or residual DMSO ( $\delta=2.50$  for <sup>1</sup>H NMR;  $\delta=39.52$  for <sup>13</sup>C NMR). High-resolution mass spectra (HRMS) were recorded from on a Qexactive spectrometer in positive electrospray ionisation (ESI) mode.

### Synthetic protocols

#### General procedure for the preparation of compounds **3b–6b**

A mixture of propargyl alcohol (**7**) (2.4 mmol, 7 equiv.), azide **8**, **9**, **10**, or **11** (0.2 mmol, 1 equiv.), and copper (II) sulphate pentahydrate (0.3 equiv.) in DMF (3 ml) in a foil-covered round bottom flask was added sodium ascorbate (0.6 equiv.). The mixture was kept stirring at room temperature overnight under Ar atmosphere. The solvent was then removed under reduced pressure and the concentrate was purified by silica gel flash column chromatography.

#### General procedure for the preparation of compounds **3a–6a**

A mixture of the alkyne **13** (0.2 mmol, 69.3 mg, 1 equiv.), azide **8**, **9**, **10**, or **11** (4.8 mmol, 1.2 equiv. per reactive group of the alkyne), and copper (II) sulphate pentahydrate (0.3 equiv. per reactive group of the alkyne) in DMF (5 ml) was added sodium ascorbate (0.6 equiv. per reactive group of the alkyne). The mixture was irradiated in a microwave at 300 W and 115 °C for 45 min. Water (10 ml) was added and the crude mixture was extracted with dichloromethane (3 × 20 ml). The organic phases were combined, dried with MgSO<sub>4</sub>, and filtered. Evaporation of the solvent by reduced pressure yielded a crude material that was purified by column chromatography.

### Cholinesterase assays

For the assessment of enzymatic inhibition, commercially available acetylcholinesterase from *Electrophorus electricus* (type V-5, Sigma Aldrich) was used, conducting minor modifications on Ellman's protocol<sup>25</sup>. Stock solutions of inhibitors were prepared in DMSO, being the solvent content of 1.25% (V/V) in the final assay solutions. Enzymatic activities were measured in a UV-Vis instrument (Hitachi U-2900) using PS cuvettes containing 0.1 mM phosphate buffer (pH 8.0), 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB, 0.88 mM, buffer solution), acetylthiocholine iodide as a model substrate, inhibitor, properly diluted aqueous enzyme solution, and water up to 1.2 ml. Solutions of the enzymes were prepared so as to keep the reaction rate within 0.12–0.15 Abs/min when  $[S] = 4 \times K_M$ . The formation of the chromophore was monitored during 125 s at 405 nm and 25 °C.

Calculation of  $IC_{50}$  values was accomplished by plotting %I vs.  $\log[I]$  and adjusting to a second-order equation. Substrate concentration was kept at 121  $\mu$ M, using 2–4 independent assays, each of them, being run in duplicate.

For the calculation of the kinetic parameters of the free enzyme, and in the presence of **3a**, five different substrate concentrations, ranging from  $1/4 K_M$  to  $4 \times K_M$  were used. Cornish-Bowden method<sup>26</sup> provided the mode of inhibition of **3a**; for that purpose, two different plots were used:  $1/v$  vs.  $[I]$  (Dixon plot) and  $[S]/v$  vs.  $[I]$ . Mixed inhibition was found for such compound, which means that it binds both, the free enzyme ( $K_{ia}$ ) and the enzyme-substrate complex ( $K_{ib}$ ). Kinetic parameters ( $K_M$ ,  $V_{max}$ ,  $K_M$  app,  $V_{max}$  app) were obtained through non-linear regression analysis (least squares fit) using the GraphPad Prism 8.01 software and inhibition constants were calculated using the following equations:

$$K_{M, app} = K_M \frac{1 + \frac{[I]}{K_{ia}}}{1 + \frac{[I]}{K_{ib}}} \quad (1)$$

$$V_{max, app} = \frac{V_{max}}{1 + \frac{[I]}{K_{ib}}} \quad (2)$$


Data are expressed as the mean  $\pm$  SD.

## Results and discussion


### Synthesis

The presence of 1,2,3-triazole moieties in the linker between the pharmacophores in bivalent cholinesterase inhibitors has been found to establish interactions with residues in AChE<sup>27</sup>. Therefore, we considered it unsuitable to employ tacrine (**1**) as a reference compound for the evaluation of the multivalent inhibition potency of **3a–6a**. Instead, for each tetra-tacrine **3a**, **4a**, **5a**, and **6a** a mono-tacrine reference compound **3b**, **4b**, **5b**, and **6b**, respectively, was prepared to contain the 1,2,3-triazole moiety and the same number of  $CH_2$ -groups between the tacrine ring and the hydroxyl group as the corresponding tetra-tacrine contains  $CH_2$ -groups between its tacrine rings and central scaffold. Reference compounds **3b–6b** were obtained when propargyl alcohol (**7**) underwent Cu(I) catalysed alkyne-azide 1,3-dipolar cycloaddition (CuAAC) with azide armed tacrine derivatives **8**<sup>28</sup> and **9–11**<sup>23a</sup> (Scheme 1).

The synthesis of the tetravalent tacrine architectures **3a–6a** commenced from commercially available methyl  $\alpha$ -D-glucopyranoside (**12**), which was subjected to propargylation upon treatment with propargyl bromide and sodium hydride to provide **13** (Scheme 2). In the final step, tetra-alkyne **13** was armed with four tacrine inhitopes when it underwent Cu(I) catalysed alkyne-azide



**Scheme 1.** Synthesis of reference compounds **3b–6b**. (i)  $CuSO_4 \cdot 5H_2O$ , sodium ascorbate, DMF, RT.



**Scheme 2.** Synthesis of tetra-tacrines **3a–6a**. (i) NaH, propargyl bromide, DMF, RT, (ii) **8**, **9**, **10**, or **11**,  $CuSO_4 \cdot 5H_2O$ , sodium ascorbate, DMF, MW, 115 °C.

1,3-dipolar cycloaddition with azides **8**, **9**, **10**, and **11** to obtain tetramers **3a**, **4a**, **5a**, and **6a**, respectively, with variable length of the linker between the central sugar scaffold and their inhitopes. The formation of 1,4-regioisomeric triazole moieties in **3a–6a** was supported with <sup>13</sup>C-NMR spectroscopy where the carbon atoms in 5-position in the triazole moieties consistently appeared in the range 124.8 to 122.7 ppm, which agrees with reported data for such isomers<sup>29</sup>. The carbons in 5-position (CH-triazole) were in turn identified through HMBC correlation with the  $CH_2$ -protons (2'-H, 3'-H, 4'-H, and 6'-H) between the triazole moieties and the central sugar scaffold (Figure 2).




Figure 2. Part of the HMBC NMR spectra of tetra-valent triazole tacrine **6a** in  $\text{CDCl}_3$  (850.13 MHz) (CH-triazole = C-5 carbons and C-CH-triazole = C-4 carbons).

### Inhibition studies

The potency of tetra-tacrines **3a–6a** and mono-tacrines **3b–6b** for the inhibition of *Electrophorus electricus* AChE were tested using the Ellman method<sup>25</sup> and the activities are presented in Table 1. All the tacrine-monomers **3b–6b** displayed potency in the nM concentration range from  $\text{IC}_{50} = 566$  nM down to  $\text{IC}_{50} = 7.1$  nM for the inhibition of AChE. The mono-tacrines with longer linkers [**5b** ( $m = 6$ ) and **6b** ( $m = 8$ )] between the tacrine and triazole rings are significantly stronger inhibitors than **3b** ( $m = 2$ ) and **4b** ( $m = 3$ ) with shorter linkers, which indicates that the longer ligands establish more efficient simultaneous interactions with PAS and CAS in the active gorge. The tetra-tacrines **3a–6a** also displayed potency in nM concentration range ( $\text{IC}_{50} = 12.5$  nM to  $\text{IC}_{50} = 232$  nM). However, for these tetra-valent inhibitors, there was no clear trend between the linker length between the tacrine and triazole rings as the strongest tetra-tacrine AChE inhibitor **5a** ( $\text{IC}_{50} = 12.5$  nM,  $m = 6$ ) behaves as a 36-fold stronger inhibitor than the weakest tetra-tacrine inhibitor **6a** ( $\text{IC}_{50} = 232$  nM,  $m = 8$ ).

The relative inhibition potency (rp) was obtained by dividing the  $\text{IC}_{50}$  value of the mono-tacrine with the  $\text{IC}_{50}$  value of the corresponding tetra-tacrine, which contains the same number of  $\text{CH}_2$ -groups between the tacrine and triazole rings [for instance,  $\text{rp} = \text{IC}_{50}(\mathbf{3b}) / \text{IC}_{50}(\mathbf{3a}) = 12.9$ ]. The relative inhibition potencies for tetra-tacrines **3a–6a** demonstrates that longer linkers between the triazole and

Table 1. Relative inhibition potencies (rp), inhibition potencies on valency-corrected basis (rp/n) for tetra-tacrines **3a–6a** and inhibitory potencies ( $\text{IC}_{50}$  [nM]) against *Electrophorus electricus* AChE by **3a–6a** and **3b–6b**.

Inhibitor	AChE $\text{IC}_{50}^a$	AChE $\text{rp}^b$	AChE $\text{rp}/n^c$
<b>3a</b>	$43.7 \pm 7.3$ nM	12.9	3.2
<b>3b</b>	$565 \pm 79$ nM	—	—
<b>4a</b>	$60.2 \pm 5.5$ nM	5.8	1.5
<b>4b</b>	$348 \pm 23$ nM	—	—
<b>5a</b>	$12.5 \pm 3.3$ nM	1.0	0.25
<b>5b</b>	$12.6 \pm 2.4$ nM	—	—
<b>6a</b>	$232 \pm 21$ nM	0.03	0.008
<b>6b</b>	$7.1 \pm 1.0$ nM	—	—
Tacrine	$53.4 \pm 1.1$ nM	—	—
Methyl $\alpha$ -D-glucopyranoside	N.I. <sup>d</sup>	—	—


<sup>a</sup>[S] = 121  $\mu\text{M}$  (S = substrate).

<sup>b</sup> $\text{rp} = \text{IC}_{50}(\text{mono-tacrine}) / \text{IC}_{50}(\text{tetra-tacrine})$ .

<sup>c</sup> $\text{rp}/n = \text{rp}/\text{number of tacrine rings}$ .

<sup>d</sup>Tested at 100  $\mu\text{M}$  inhibitor concentration.

tacrine rings have a destructive impact on the inhibition potency, as the rp-values gradually decrease from  $\text{rp} = 12.9$  for **3a** ( $m = 2$ ) to  $\text{rp} = 0.03$  for **6a** ( $m = 8$ ). The inhibition potencies on valency-corrected basis (rp/n) showed that tetra-tacrines **3a** ( $\text{rp}/n = 3.2$ ,  $m = 2$ ) and **4a** ( $\text{rp}/n = 1.5$ ,  $m = 3$ ) exhibit small but significant multivalent inhibition potencies for AChE. The rp/n-values for **5a** ( $\text{rp}/n = 0.25$ ,  $m = 6$ ) and



**Figure 3.** Cornish-Bowden plots for compound **3a** against electrophorus electricus AChE (V: rate of reaction; [S]: substrate concentration; [I]: inhibitor concentration).

**6a** ( $rp/n=0.008$ ,  $m=8$ ) on the other hand demonstrate that the mono-tacrines **5b** ( $m=6$ ) and **6b** ( $m=8$ ) were 75% and more than 99% less active, respectively, when they are connected to the central multivalent sugar scaffold. From a Cornish-Bowden plot (Figure 3) for **3a**, we concluded that it causes a mixed inhibition mode of AChE [ $K_{ia} = 31.6 \pm 2.0$  nM (competitive inhibition constant) and  $K_{ib} = 45.0 \pm 5.9$  nM (non-competitive inhibition constant)], which implies that it binds to the catalytic site in addition to a second binding site, for instance, PAS on the entrance of the active gorge. Thus, the multivalent inhibitory potency observed for **3a** and **3b** might be due to the chelation effect in which the length of the linkers in **3a** and **4a** are of sufficient length to allow simultaneous binding of their tacrine inhitopes to more than one active gorge in the tetrameric AChE enzyme. On the other hand, shorter linkers in the tetra-tacrines imply higher effective concentration nearby the active gorges, and thus a statistical binding effect cannot be excluded as the reason for the observed multivalent inhibition potency observed for tetra-tacrines **3a** and **4a**. However, as  $rp/n < 1$  for **5a** and **6a**, in such statistical binding effect scenario, it implies that another effect is involved, which oppose the binding of the inhitopes to the enzyme for example that longer linkers affect the position of the tacrine rings in such a way that they become less accessible for the enzyme.

## Conclusions

We have applied the Cu(I)-catalysed azide-alkyne Huisgen cycloaddition reaction to obtain four tetra-tacrine clusters **3a-6a** in which the tacrine rings are connected to a central scaffold *via* linkers of variable lengths. Two of the tetra-tacrines **3a** and **4a** with the shortest linkers displayed a small but significant multivalent effect in the inhibition of AChE. The observed multivalent inhibition potency is proposed to arise from the chelation or statistical binding effects.

## Acknowledgements

We thank Associate Professor Kåre B. Jørgensen for keeping the NMR instrument in good condition. Thanks, are also due to Associate Professor Jarl Underhaug, University of Bergen, for the skillful performance of 850.13 MHz NMR analysis.

## Author contributions

EL: conceptualisation. TCSE and ÓL: methodology. EL, MOS, SBF, ÓL, and JGFB: funding acquisition. EL, TCSE, and ÓL: investigation.

EL: project administration. EL, ÓL, MOS, and JGFB: resources. EL and MOS: supervision. EL: writing – original draft. EL, ÓL, TCSE, MOS, SBF, and JGFB: writing – review and editing.

## Disclosure statement

No potential conflict of interest was reported by the authors.

## Funding

This work was supported by the Junta de Andalucía (FQM134), University of Stavanger, Ministerio de Ciencia e Innovación of Spain (MICINN) (CTQ2016-78703-P), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES) and European Regional Development Fund (FEDER).

## References

- Mammen M, Choi SK, Whitesides GM. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. *Angew Chem Int Ed* 1998;37:2754–94.
- (a) Compain P. Multivalent effect in glycosidase inhibition: the end of the beginning. *Chem Rec* 2020;20:10–22. (b) Lundquist JJ, Toone EJ. The cluster glycoside effect. *Chem Rev* 2002;102:555–78. (c) Lee YC, Lee RT. Carbohydrate-protein interactions: basis of glycobiology. *Acc Chem Res* 1995; 28:321–7.
- (a) González-Cuesta M, Mellet CO, Fernández JMG. Carbohydrate supramolecular chemistry: beyond the multivalent effect. *Chem Commun* 2020;56:5207–22. (b) Martínez Á, Mellet CO, Fernández JMG. Cyclodextrin-based multivalent glycoconjugates: covalent and supramolecular conjugates to assess carbohydrate-protein interactions. *Chem Soc Rev* 2013;42:4746–73. (c) Chabre YM, Roy R. Design and creativity in synthesis of multivalent neoglycoconjugates. *Adv Carbohydr Chem Biochem* 2010;63:165–393.
- (a) Marra A, Staderini S, Berthet N, et al. Thiyl glycosylation of propargylated octasilsesquioxane: synthesis and lectin-binding properties of densely glycosylated clusters on a cubic platform. *Eur J Org Chem* 2013;2013:1144–9. (b) Lo Conte M, Staderini S, Chambery A, et al. Glycoside and peptide clustering around the octasilsesquioxane scaffold via photoinduced free-radical thiolene coupling. The observation of a striking glycoside cluster effect. *Org Biomol Chem*

- 2012;10:3269–77.(c) Kitov PI, Sadowska JM, Mulvey G, et al. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. *Nature* 2000;403:669–72.
5. (a) Nierengarten I, Nierengarten JF. Fullerene sugar balls: a new class of biologically active fullerene derivatives. *Chem Asian J* 2014;9:1436–44. (b) Kanfar N, Bartolami E, Zelli R, et al. Emerging trends in enzyme inhibition by multivalent nanoconstructs. *Org Biomol Chem* 2015;13:9894–906.
  6. Fasting C, Schalley CA, Weber M, et al. Multivalency as a chemical organization and action principle. *Angew Chem Int Ed Engl* 2012;51:10472–98.
  7. (a) Assailly C, Bridot C, Saumonneau A, et al. Polyvalent transition-state analogues of sialyl substrates strongly inhibit bacterial sialidases. *Chemistry* 2021;27:3142–50. (b) Compain P, Bodlenner A. The multivalent effect in glycosidase inhibition: a new, rapidly emerging topic in glycoscience. *ChemBioChem* 2014;15:1239–51.(c) Gouin SG. Multivalent Inhibitors for carbohydrate-processing enzymes: beyond the “lock-and-key concept”. *Chemistry* 2014;20:11616–28.
  8. Tikad A, Fu H, Sevrain CM, et al. Mechanistic insight into heptosyltransferase inhibition by using Kdo multivalent glycoclusters. *Chemistry* 2016;22:13147–55.
  9. (a) Carta F, Osman SM, Vullo D, et al. Dendrimers incorporating benzenesulfonamide moieties strongly inhibit carbonic anhydrase isoforms I–XIV. *Org Biomol Chem* 2015;13:6453–7. (b) Touisni N, Kanfar N, Ulrich S, et al. Fluorescent silica nanoparticles with multivalent inhibitory effects towards carbonic anhydrases. *Chem Eur J* 2015;21:10306–9.(c) Kanfar N, Tanc M, Dumy P, et al. Effective access to multivalent inhibitors of carbonic anhydrases promoted by peptide bioconjugation. *Chemistry* 2017;23:6788–94.(d) Carta F, Dumy P, Supuran CT, Winum JY. Multivalent carbonic anhydrases inhibitors. *Int J Mol Sci* 2019;20:5352.
  10. (a) Zhao S, Xu J, Zhang S, et al. Multivalent butyrylcholinesterase inhibitor discovered by exploiting dynamic combinatorial chemistry. *Bioorg Chem* 2021;108:104656. (b) Xu J, Zhao S, Zhang S, et al. Development of a multivalent acetylcholinesterase inhibitor via dynamic combinatorial chemistry. *Int J Biol Macromol* 2020;150:1184–91.
  11. Lepage ML, Schneider JP, Bodlenner A, et al. Iminosugar-cyclopeptide conjugates raise multivalent effect in glycosidase inhibition at unprecedented high levels. *Chemistry* 2016;22:5151–5.
  12. (a) Joosten A, Schneider JP, Lepage ML, et al. A convergent strategy for the synthesis of second-generation iminosugar clusters using “clickable” trivalent dendrons. *Eur J Org Chem* 2014;2014:1866–72. (b) Brissonnet Y, Ladevèze S, Tezé D, et al. Polymeric iminosugars improve the activity of carbohydrate-processing enzymes. *Bioconjug Chem* 2015;26:766–72.
  13. Brissonnet Y, Mellet CO, Morandat S, et al. Topological effects and binding modes operating with multivalent iminosugar-based glycoclusters and mannosidases. *J Am Chem Soc* 2013;135:18427–35.
  14. (a) Schneider JP, Tommasone S, Sala PD, et al. Synthesis and glycosidase inhibition properties of calix[8]arene-based iminosugar click clusters. *Pharmaceuticals* 2020;13:366. (b) Decroocq C, Joosten A, Sergent R, et al. The multivalent effect in glycosidase inhibition: probing the influence of valency, peripheral ligand structure, and topology with cyclodextrin-based iminosugar click clusters. *ChemBioChem* 2013;14:2038–49.
  15. Alzheimer’s Association. 2016 Alzheimer’s disease facts and figures. *Alzheimers Dement* 2016;12:459–509.
  16. Craig LA, Hong NS, McDonald RJ. Revisiting the cholinergic hypothesis in the development of Alzheimer’s disease. *Neurosci Biobehav Rev* 2011;35:1397–409.
  17. Bartus RT, Dean RL, III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. *Science* 1982; 217:408–14.
  18. Anand P, Singh B. A review on cholinesterase inhibitors for Alzheimer’s disease. *Arch Pharm Res* 2013;36:375–99.
  19. Sharma K. Cholinesterase inhibitors as Alzheimer’s therapeutics. *Mol Med Rep* 2019;20:1479–87.
  20. Sussman JL, Harel M, Frolow F, et al. Atomic structure of acetylcholinesterase from *Torpedo californica*: a prototypic acetylcholine-binding protein. *Science* 1991;253:872–9.
  21. Harel M, Schalk I, Ehret-Sabatier L, et al. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. *Proc Natl Acad Sci USA* 1993;90:9031–5.
  22. Pang YP, Quiram P, Jelacic T, et al. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer’s disease. *J Biol Chem* 1996;271:23646–9.
  23. (a) de Santana QLO, Evangelista TCS, Imhof P, et al. Tacrine-sugar mimetic conjugates as enhanced cholinesterase inhibitors. *Org Biomol Chem* 2021;19:2322–37. (b) Ahuja-Casarín AI, Merino-Montiel P, Vega-Baez JL, et al. Tuning the activity of iminosugars: novel N-alkylated deoxynojirimycin derivatives as strong BuChE inhibitors. *J Enzyme Inhib Med Chem* 2021;36:138–46.(c) Kozurkova M, Hamulakova S, Gazova Z, et al. Neuroactive multifunctional tacrine congeners with cholinesterase, anti-amyloid aggregation and neuroprotective properties. *Pharmaceuticals* 2011;4:382–418.
  24. (a) Bourne Y, Grassi J, Bougis PE, Marchot P. Conformational flexibility of the acetylcholinesterase tetramer suggested by X-ray crystallography. *J Biol Chem* 1999;274:30370–6. (b) Fernandez HL, Moreno RD, Inestrosa NC. Tetrameric (G4) acetylcholinesterase: structure, localization, and physiological regulation. *J Neurochem* 1996;66:1335–46.
  25. Ellman GL, Courtney KD, Andres V, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem Pharmacol* 1961;7:88–95.
  26. Cornish-Bowden A. A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. *Biochem J* 1974;137:143–4.
  27. Najafi Z, Mahdavi M, Saeedi M, et al. Novel tacrine-coumarin hybrids linked to 1,2,3-triazole as anti-Alzheimer’s compounds: *in vitro* and *in vivo* biological evaluation and docking study. *Bioorg Chem* 2019;83:303–16.
  28. Oukoloff K, Coquelle N, Bartolini M, et al. Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3. *Eur J Med Chem* 2019;168:58–77.
  29. Creary X, Anderson A, Brophy C, et al. Method for assigning structure of 1,2,3-triazoles. *J Org Chem* 2012;77:8756–61.